Cargando…

A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods

The NRF2 transcription factor is a key regulator in cellular oxidative stress response, and acts as a tumor suppressor. Aberrant activation of NRF2 has been implicated in promoting chemo‐resistance, tumor growth, and metastasis by activating its downstream target genes. Hence, inhibition of NRF2 pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Brüschweiler, Sven, Fuchs, Julian E., Bader, Gerd, McConnell, Darryl B., Konrat, Robert, Mayer, Moriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293343/
https://www.ncbi.nlm.nih.gov/pubmed/34524728
http://dx.doi.org/10.1002/cmdc.202100458
_version_ 1784749608328495104
author Brüschweiler, Sven
Fuchs, Julian E.
Bader, Gerd
McConnell, Darryl B.
Konrat, Robert
Mayer, Moriz
author_facet Brüschweiler, Sven
Fuchs, Julian E.
Bader, Gerd
McConnell, Darryl B.
Konrat, Robert
Mayer, Moriz
author_sort Brüschweiler, Sven
collection PubMed
description The NRF2 transcription factor is a key regulator in cellular oxidative stress response, and acts as a tumor suppressor. Aberrant activation of NRF2 has been implicated in promoting chemo‐resistance, tumor growth, and metastasis by activating its downstream target genes. Hence, inhibition of NRF2 promises to be an attractive therapeutic strategy to suppress cell proliferation and enhance cell apoptosis in cancer. Direct targeting of NRF2 with small‐molecules to discover protein‐DNA interaction inhibitors is challenging as it is a largely intrinsically disordered protein. To discover molecules that bind to NRF2 at the DNA binding interface, we performed an NMR‐based fragment screen against its DNA‐binding domain. We discovered several weakly binding fragment hits that bind to a region overlapping with the DNA binding site. Using SAR by catalogue we developed an initial structure‐activity relationship for the most interesting initial hit series. By combining NMR chemical shift perturbations and data‐driven docking, binding poses which agreed with NMR information and the observed SAR were elucidated. The herein discovered NRF2 hits and proposed binding modes form the basis for future structure‐based optimization campaigns on this important but to date ‘undrugged’ cancer driver.
format Online
Article
Text
id pubmed-9293343
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92933432022-07-20 A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods Brüschweiler, Sven Fuchs, Julian E. Bader, Gerd McConnell, Darryl B. Konrat, Robert Mayer, Moriz ChemMedChem Full Papers The NRF2 transcription factor is a key regulator in cellular oxidative stress response, and acts as a tumor suppressor. Aberrant activation of NRF2 has been implicated in promoting chemo‐resistance, tumor growth, and metastasis by activating its downstream target genes. Hence, inhibition of NRF2 promises to be an attractive therapeutic strategy to suppress cell proliferation and enhance cell apoptosis in cancer. Direct targeting of NRF2 with small‐molecules to discover protein‐DNA interaction inhibitors is challenging as it is a largely intrinsically disordered protein. To discover molecules that bind to NRF2 at the DNA binding interface, we performed an NMR‐based fragment screen against its DNA‐binding domain. We discovered several weakly binding fragment hits that bind to a region overlapping with the DNA binding site. Using SAR by catalogue we developed an initial structure‐activity relationship for the most interesting initial hit series. By combining NMR chemical shift perturbations and data‐driven docking, binding poses which agreed with NMR information and the observed SAR were elucidated. The herein discovered NRF2 hits and proposed binding modes form the basis for future structure‐based optimization campaigns on this important but to date ‘undrugged’ cancer driver. John Wiley and Sons Inc. 2021-10-08 2021-12-06 /pmc/articles/PMC9293343/ /pubmed/34524728 http://dx.doi.org/10.1002/cmdc.202100458 Text en © 2021 The Authors. ChemMedChem published by Wiley-VCH GmbH https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Full Papers
Brüschweiler, Sven
Fuchs, Julian E.
Bader, Gerd
McConnell, Darryl B.
Konrat, Robert
Mayer, Moriz
A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods
title A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods
title_full A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods
title_fullStr A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods
title_full_unstemmed A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods
title_short A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods
title_sort step toward nrf2‐dna interaction inhibitors by fragment‐based nmr methods
topic Full Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293343/
https://www.ncbi.nlm.nih.gov/pubmed/34524728
http://dx.doi.org/10.1002/cmdc.202100458
work_keys_str_mv AT bruschweilersven asteptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods
AT fuchsjuliane asteptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods
AT badergerd asteptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods
AT mcconnelldarrylb asteptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods
AT konratrobert asteptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods
AT mayermoriz asteptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods
AT bruschweilersven steptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods
AT fuchsjuliane steptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods
AT badergerd steptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods
AT mcconnelldarrylb steptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods
AT konratrobert steptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods
AT mayermoriz steptowardnrf2dnainteractioninhibitorsbyfragmentbasednmrmethods